Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.

van Ingen, Iris L A; Lamers-Karnebeek, Femke; Jansen, Tim L

van Ingen, Iris L A; Lamers-Karnebeek, Femke; Jansen, Tim L.

Affiliation

van Ingen IL; Radboud University Medical Center, Department of Rheumatology , POB 9101, 6500 HB Nijmegen , The Netherlands Tim.Jansen@Radboudumc.nl.

Expert Opin Biol Ther ; 14(12): 1761-7, 2014 Dec.

Article in En | MEDLINE | ID: mdl-25366268

Subject(s)

Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/drug therapy; Tumor Necrosis Factor-alpha/antagonists & inhibitors; Withholding Treatment; Disease Progression; Drug Administration Schedule; Humans; Methotrexate/therapeutic use; Neoplasm, Residual; Remission Induction/methods; Treatment Outcome

Key words

TNFi; TNFα; biological disease-modifying antirheumatic drugs; rheumatoid arthritis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Tumor Necrosis Factor-alpha / Antirheumatic Agents / Withholding Treatment Type of study: Prognostic_studies Limits: Humans Language: En Journal: Expert Opin Biol Ther Journal subject: BIOLOGIA / TERAPEUTICA Year: 2014 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google